Adjuvant effect of bacterial outer membrane vesicles with penta-acylated lipopolysaccharide on antigen-specific T cell priming

Vaccine

Volumn 29, Issue 46, 2011, Pages 8293-8301

  Lee, Dong Ho ^a,b   Kim, Sang Hyun ^c   Kang, Wonseok ^a   Choi, Yoon Seok ^a   Lee, Sang Ho ^c   Lee, Sang Rae ^c   You, Sooseong ^a   Lee, Heung Kyu ^a   Chang, Kyu Tae ^c   Shin, Eui Cheol ^a  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^b Daejeon St Mary's Hospital   (South Korea)

^c Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

Adjuvant; Outer membrane vesicles; Penta acylated LPS; T cells

Indexed keywords

CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 6; KEYHOLE LIMPET HEMOCYANIN; LIPOPOLYSACCHARIDE; METALLOPROTEIN; OT 1 PEPTIDE; OVALBUMIN; RANTES; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BACTERIAL OUTER MEMBRANE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; ESCHERICHIA COLI; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; MEMBRANE VESICLE; MOUSE; NONHUMAN; OUTER MEMBRANE VESICLE; PRIORITY JOURNAL; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CYTOKINES; ESCHERICHIA COLI; EXOSOMES; FETAL PROTEINS; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PEPTIDES; T-BOX DOMAIN PROTEINS; T-LYMPHOCYTES;

EID: 80053955302     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.08.102     Document Type: Article

References (30)

1. Koup R.A., Graham B.S., Douek D.C. The quest for a T cell-based immune correlate of protection against HIV: a story of trials and errors. Nat Rev Immunol 2011, 11:65-70.
2. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest 2009, 119:1745-1754.
3. Rappuoli R. Bridging the knowledge gaps in vaccine design. Nat Biotechnol 2007, 25:1361-1366.
4. Beveridge T.J. Structures of Gram-negative cell walls and their derived membrane vesicles. J Bacteriol 1999, 181:4725-4733.
5. Kuehn M.J., Kesty N.C. Bacterial outer membrane vesicles and the host pathogen interaction. Genes Dev 2005, 19:2645-2655.
6. Kolling G.L., Matthews K.R. Export of virulence genes and Shiga toxin by membrane vesicles of Escherichia coli O157:H7. Appl Environ Microbiol 1999, 65:1843-1848.
7. Aldick T., Bielaszewska M., Uhlin B.E., Humpf H.U., Wai S.N., Karch H. Vesicular stabilization and activity augmentation of enterohaemorrhagic Escherichia coli haemolysin. Mol Microbiol 2009, 71:1496-1508.
8. Kim S.H., Lee S.R., Kim K.S., Ko A., Kim E., Kim Y.H., et al. Shiga toxin A subunit mutant of Escherichia coli O157:H7 releases outer membrane vesicles containing the B-pentameric complex. FEMS Immunol Med Microbiol 2010, 58:412-420.
9. Mullaney E., Brown P.A., Smith S.M., Botting C.H., Yamaoka Y.Y., Terres A.M., et al. Proteomic and functional characterization of the outer membrane vesicles from the gastric pathogen Helicobacter pylori. Proteomics Clin Appl 2009, 3:785-796.
10. Alaniz R.C., Deatherage B.L., Lara J.C., Cookson B.T. Membrane vesicles are immunogenic facsimiles of Salmonella typhimurium that potently activate dendritic cells, prime B and T cell responses, and stimulate protective immunity in vivo. J Immunol 2007, 179:7692-7701.
11. Norheim G., Aase A., Caugant D.A., Høiby E.A., Fritzsønn E., Tangen T., et al. Development and characterization of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis. Vaccine 2005, 23:3762-3774.
12. Schild S., Nelson E.J., Bishop A.L., Camilli A. Characterization of Vibrio cholerae outer membrane vesicles as a candidate vaccine for cholera. Infect Immun 2009, 77:472-484.
13. Kim S.H., Kim K.S., Lee S.R., Kim E., Kim M.S., Lee E.Y., et al. Structural modifications of outer membrane vesicles to refine them as vaccine delivery vehicles. Biochim Biophys Acta 2009, 1788:2150-2159.
14. Fisseha M., Chen P., Brandt B., Kijek T., Moran E., Zollinger W. Characterization of native outer membrane vesicles from lpxL mutant strains of Neisseria meningitidis for use in parenteral vaccination. Infect Immun 2005, 73:4070-4080.
15. Teghanemt A., Zhang D., Levis E.N., Weiss J.P., Gioannini T.L. Molecular basis of reduced potency of underacylated endotoxins. J Immunol 2005, 175:4669-4676.
16. Feodorova V.A., Pan'kina L.N., Savostina E.P., Sayapina L.V., Motin V.L., Dentovskaya S.V., et al. A Yersinia pestis lpxM-mutant live vaccine induces enhanced immunity against bubonic plague in mice and guinea pigs. Vaccine 2007, 25:7620-7628.
17. Liu T., Konig R., Sha J., Agar S.L., Tseng C.T., Klimpel G.R., et al. Immunological responses against Salmonella enterica serovar Typhimurium Braun lipoprotein and lipid A mutant strains in Swiss-Webster mice: potential use as live-attenuated vaccines. Microb Pathog 2008, 44:224-237.
18. Ranallo R.T., Kaminski R.W., George T., Kordis A.A., Chen Q., Szabo K., et al. Virulence, inflammatory potential, and adaptive immunity induced by Shigella flexneri msbB mutants. Infect Immun 2010, 78:400-412.
19. Bishop R.E. The lipid A palmitoyltransferase PagP: molecular mechanisms and role in bacterial pathogenesis. Mol Microbiol 2005, 57:900-912.
20. Smith A.E., Kim S.H., Liu F., Jia W., Vinogradov E., Gyles C.L., et al. PagP activation in the outer membrane triggers R3 core oligosaccharide truncation in the cytoplasm of Escherichia coli O157:H7. J Biol Chem 2008, 283:4332-4343.
21. Datsenko K.A., Wanner B.L. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci USA 2000, 97:6640-6645.
22. Hitchcock P.J., Brown T.M. Morphological heterogeneity among Salmonella lipopolysaccharide chemotypes in silver-stained polyacrylamide gels. J Bacteriol 1983, 154:269-277.
23. Haneberg B., Dalseg R., Wedege E., Hoiby E.A., Haugen I.L., Oftung F., et al. Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans. Infect Immun 1998, 66:1334-1341.
24. Drabick J.L., Brandt B.L., Moran E.E., Saunders N.B., Shoemaker D.R., Zollinger W.D. Safety and immunogenicity testing of an intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers. Vaccine 1999, 18:160-172.
25. Oftung F., Naess L.M., Wetzler L.M., Korsvold G.E., Aase A., Hoiby E.A., et al. Antigen-specific T-cell responses in humans after intranasal immunization with a meningococcal serogroup B outer membrane vesicle vaccine. Infect Immun 1999, 67:921-927.
26. Fredriksen J.H., Rosenqvist E., Wedege E., Bryn K., Bjune G., Frøholm L.O., et al. Production, characterization and control of MenB-vaccine Folkehelsa: an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann 1991, 14:67-80.
27. Keiser P.B., Gibbs B.T., Coster T.S., Moran E.E., Stoddard M.B., Labrie J.E., et al. A phase 1 study of a group B meningococcal native outer membrane vesicle vaccine made from a strain with deleted lpxL2 and synX and stable expression of opcA. Vaccine 2010, 28:6970-6976.
28. Keiser P.B., Biggs-Cicatelli S., Moran E.E., Schmiel D.H., Pinto V.B., Burden R.E., et al. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine 2011, 29:1413-1420.
29. Durand V., Mackenzie J., de Leon J., Mesa C., Quesniaux V., Montoya M., et al. Role of lipopolysaccharide in the induction of type I interferon-dependent cross-priming and IL-10 production in mice by meningococcal outer membrane vesicles. Vaccine 2009, 27(18):1912-1922.
30. Williams J.N., Skipp P.J., Humphries H.E., Christodoulides M., O'Connor C.D., Heckels J.E. Proteomic analysis of outer membranes and vesicles from wild-type serogroup B Neisseria meningitidis and a lipopolysaccharide-deficient mutant. Infect Immun 2007, 75:1364-1372.